Annexon (ANNX) grants CMO 225,000 options and 56,250 RSUs

Rhea-AI Filing Summary

Annexon, Inc. reported that its Chief Medical Officer, Jamie Dananberg, received new equity awards on February 19, 2026. The awards include a stock option covering 225,000 shares at an exercise price of $0.00 per share and a grant of 56,250 shares of common stock in the form of restricted stock units (RSUs).

According to the filing, 1/48 of the option shares vest monthly starting from February 19, 2026, becoming fully vested on the fourth anniversary, subject to continued service. For the RSUs, one-third vests each year on February 19, with the first third vesting on February 19, 2027, also conditioned on continuous service. Following these grants, Dananberg directly owns 129,402 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Dananberg Jamie

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	225,000	$0.00	--
Grant/Award	Common Stock	56,250	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 225,000 shares (Direct); Common Stock — 129,402 shares (Direct)

Footnotes (1)

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dananberg Jamie

(Last) (First) (Middle)

C/O ANNEXON, INC.

1400 SIERRA POINT PKWY, BLDG C, STE 200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Annexon, Inc. [ ANNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		A		56,250(1)	A	$0	129,402	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.1	02/19/2026		A		225,000		(2)	02/19/2036	Common Stock	225,000	$0	225,000	D

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

2. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Jennifer Lew, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Annexon (ANNX) grant to its Chief Medical Officer?

Annexon granted its Chief Medical Officer a stock option for 225,000 shares at $0.00 per share and 56,250 RSUs. These awards are part of his compensation and vest over several years, contingent on continued service.

How do Jamie Dananberg’s new stock options at Annexon (ANNX) vest?

The stock option for 225,000 shares vests in equal monthly installments. Specifically, 1/48 of the shares vest on each monthly anniversary of February 19, 2026, so the option becomes fully vested four years after that date, assuming continued service.

What is the vesting schedule for the RSUs granted by Annexon (ANNX)?

The 56,250 RSUs vest in three equal annual installments. One-third of the RSUs vests on February 19, 2027, and the remaining thirds vest on the next two February 19 dates, subject to continuous service with Annexon at each vesting date.

How many Annexon (ANNX) common shares does Jamie Dananberg own after these grants?

After the equity grants, Jamie Dananberg directly holds 129,402 shares of Annexon common stock. This total reflects his updated ownership position following the award of 56,250 RSUs on February 19, 2026, as reported in the insider filing.

Are the new Annexon (ANNX) equity awards open-market purchases by the CMO?

No, the filing characterizes these as grants or awards, not open-market purchases. The stock option and RSUs were awarded at an exercise or purchase price of $0.00 per share as part of compensation, and vest over time with continued service.